Combination therapy for the treatment of estrogen-sensitive dise

Details Combination therapy for the treatment of estrogen-sensitive dise Combination therapy for the treatment of estrogen-sensitive dise

1991-11-04

1996-08-27

Jordan, Kimberly

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

514 15, 514169, 514170, 514161, 514255, 514328, 514649, 514617, A61K 3800, A61K 3156, A61K 31495, A61K 3150, A61K 31445, A61K 31165, A61K 31135

Patent

active

055501079

ABSTRACT:
A method of treatment of breast and endometrial cancer in susceptible warm-blooded animals may include inhibition of ovarian hormonal secretion by surgical (ovariectomy) or chemical (use of an LHRH agonist, e.g. [D-Trp.sup.6, des-Gly-NH.sub.2.sup.10 ]LHRH ethylamide or antagonist) as part of a combination therapy comprising administering an antiestrogen together with at least one compound selected from the group consisting of an androgen, a progestin, at least one inhibitor of sex steroid formation, especially 17.beta.-hydroxysteroid dehydrogenase and aromatase activity, at least one inhibitor of prolactin secretion, one inhibitor of growth hormone secretion and one inhibitor of ACTH secretion. Pharmaceutical compositions useful for such treatment and pharmaceutical kits containing such composition are disclosed.

REFERENCES:
patent: 3061616 (1962-10-01), Camero et al.
patent: 3127427 (1964-03-01), Boller et al.
patent: 3752814 (1973-08-01), Fluckiger et al.
patent: 4024248 (1977-05-01), Konig et al.
patent: 4071622 (1978-01-01), Johnson et al.
patent: 4094994 (1978-06-01), Schonenberger et al.
patent: 4100274 (1979-07-01), Dutta et al.
patent: 4118483 (1979-10-01), Konig et al.
patent: 4472382 (1984-09-01), Labrie et al.
patent: 4481190 (1984-11-01), Nestor et al.
patent: 4650787 (1987-03-01), Schally et al.
patent: 4732912 (1988-03-01), Pilgrim et al.
patent: 4751240 (1988-06-01), Bowler et al.
patent: 4760053 (1988-07-01), Labrie
patent: 4760061 (1988-07-01), Edwards et al.
patent: 4775660 (1988-10-01), Labrie et al.
patent: 4775661 (1988-10-01), Labrie
Adair, Surg. Gynecol. Obstet. 84:719-722 (1947).
Adair, et al., JAMA 140:1193-2000 (1949).
Adair, et al., Ann. Surg. 123:1023-1035 (1946).
Beardwell et al., Cancer Chemo. Pharmacol. 10(3):158-160 (1983).
Brodie, et al., Steroids 38:693-702 (1981).
Bryan et al., Cancer 54:2436-2440 (1984).
Bucourt, et al., J. Biol. Chem. 253:8221-8228 (1978).
Centola, Cancer Res. 45:6264-6267 (1985).
Chan, et al., (1987) Biochem. Biophys. Res. Comm. 144(1):166-171.
Cooperative Breast Cancer Group, JAMA 188:1069-1072 (1964).
Corbin, et al., (1984) J. Steroid Biochem., 20(6B):1369, No. A9.
Covey, et al., Cancer Res. 42:3327s-3333s (1982).
Coy, et al., J. Med. Chem. 19(3):423-425 (1976).
Dutta, et al., J. Med. Chem. 21(10):1018-1024 (1978).
Engelsman, et al., Brit. J. Cancer 30:177 (1975).
Erchegyi, et al., Biochem. Biophys. Res. Comm. 100(3):915-920 (1981).
Ernshaw, et al., Clin. Endo. 21:13-21 (1984).
Giudici, et al., J. Steroid Biochem. 30:391-394 (1988).
Goldenberg, et al., JAMA 223:1267-1268 (1973).
Henderson, et al., J. Steroid Biochem. 24:303-306 (1986).
Hilf, Handbook of Experimental Pharmacology 43:191-210 (1976).
Kennedy, et al., Geriatrics 25:106-112 (1970).
Kennedy, et al., Cancer 21:197-201 (1967).
Klijn, et al., J. Steroid Biochem. 20:A33 No. 1381 (1984).
Rivier, J. Ster. Bio., 20:A2 No. 1365 (1984).
Labrie, et al., J. Steroid Biochem. 28:379-384 (1987).
Labrie, et al., The Prostate, 4:579-584 (1983).
Lamb, Am. J. Sports Medicine 12:31-38 (1984).
Lambert, et al., Ann. Clin. Biochem. 23,225-229 (1986).
Lippman, et al., Cancer Res. 36:4610-4618 (1976).
Lippman, et al., Cancer 38:868-874 (1976).
Luthy, et al., J. Steroid Biochem. 31:845-852 (1988).
Maass, et al., J. Steroid Biochem. 6:743-749 (1975).
Manni, et al., Cancer 48:2507-2509 (1981).
Manni, et al., Endocr. Rev. 7:89-94 (1986).
Mouridsen, et al., Cancer Treatm. Rev. 5:131-141 (1978).
Nathanson, et al., Rec. Prog. Horm. Res. 1:261-291 (1947).
Nestor, Jr., et al., (1984) J. Steroid Biochem., 20 (6B), 1366.
Nicholson, et al., Brit. J. Cancer 39:268-273 (1979).
Nicholson, et al., J. Ster. Biochem. 23:843-848 (1985).
Plante, et al., J. Steroid Biochem. 31:61-64 (1988).
Potts, et al., Steroids 32:257-267 (1978).
Poulin, et al., Breast Cancer Res. Treatm. 12:213-225 (1989).
Poyet, et al., The Prostate 9:237-246 (1986).
Raynaud, et al., Mechanisms of Steroid Action 145-158 (1981).
Raynaud, et al., J. Steroid Biochem 25:811-833 (1986).
Raynaud, et al., Innovative Approaches in Drug Res., 47-72 (1986).
Raynaud, et al., J. Steroid Biochem 12:143-157 (1980).
Redding, et al., Proc. Natl. Acad. Sci. USA 80:1459-1462 (1983).
Robinson, et al., J. Steroid Biochem. 21:601-605 (1984).
Sandberg, et al., Pharmac. Ther. 36:263-307 (1988).
Schally, et al., Cancer Treatment Reports 68(1):281-289 (1984).
Stewart, et al., Solid Phase Peptide Sythesis (1969).
Taylor, J. Endocr., 113:489-493 (1987).
Teulings, et al., Cancer Res. 40:2557-2561 (1980).
Thomas, et al., J. Biol. Chem. 258(3):1587-1590 (1983).
Thomas, et al., J. Biol. Chem. 258:11500-11503 (1983).
Van Veelen, et al., Cancer 58:7-13 (1986).
Vicens, et al., Expansion Scientifique 2:2139-2158 (1988).
Williams, et al., Cancer Treatment Reports, 71(12):1197-1201 (1987).
Poulin, Androgen and glucocorticoid receptor-mediated inhibition . . . , Breast Cancer Res. Treatm. 13:161-172 (1989).
Poulin, Inhibition of estrogen-dependent cell proliferation . . . , Breast Cancer Res. Treatm. 13:265-276 (1989).
Coombes, et al., Br. J. Cancer 46(1):30-4 (1982).
Neumannova, et al., Obstet. Gynecol. 66(5):695-700 (1985).
Robel, et al., Prog. Clin. Bio. Res. 142(Horm. Cancer):167-79 (1984).
Fukutomi, et al., Jpn. J. Cancer Res. (GANN) 77(1):92-7 (1986).
Grenman, et al., Gynecol. Oncol. 30(2):239-50 (1988).
Ishikawa, et al., Horumon to Rinsho 35(12):1359-66 (1987).
Tominaga, et al., Jpn. J. Cancer Res. (GANN) 76(11):1120-5 (1985).
Chemical Abstracts, vol. 104, No. 62317h, Mar. 20, 1986.
Chemical Abstracts, vol. 104, No. 142440h, May 22, 1986.
Chemical Abstracts, vol. 108, No. 198573d, Jun. 27, 1988.
Chemical Abstracts, vol. 109, No. 32346c, Sep. 1, 1988.
Davidson and Lippman, Oncogenesis 1: 89-111, 1989.
Tormey et al., Cancer Treatm. Rep., 60: 1451-1459, 1976.
Wynder, et al., Cancer, 19: 489-520, 1966.
Ayoub, et al., Gynecol. Oncol. 31(2):327-337 (1988).
Buzdar, et al., Cancer 50:1708-1712 (1982).
Cavalli, et al., J. Clin. Oncol. 2:414 (1984).
Covey, et al., Endocrinology 108:1597-1599 (1981).
Coy, et al., (1982) Endocrinology 110:1445-1447.
Gompel, et al., J. Clin. Endo. Metab. 63:1174-1180 (1986).
Harvey, et al., LHRH and its Analogs (1984).
Huggins, et al., Cancer Res. 12:134-141 (1952).
Johnson, et al., Brit. J. Cancer 50:363 (1984).
Johnston, et al., Endocrinology 115:776-785 (1984).
Klijn, et al., Lancet 1:1213-1216 (1982).
Labrie, et al., Fertil. Steril. 31:29-34 (1979).
Luthy, et al., J. Gynecol. Endo. 1:151-158 (1987).
Manni, et al., J. Natl. Cancer Inst. 74:941-944 (1985).
Minton, Cancer 33:358-363 (1974).
Robustelli della Cuna, Farmitalia Carlo Erba, S.P.A. (1987).
Welch, et al., Cancer Res. 30:1024-029 (1970).
Poulin, et al. "Stimulation of Cell Proliferation and Estrogenic Response by Adrenal C.sub.19 -.DELTA..sup.5 -Steroids in the ZR-75-1 Human Breast Cancer Cell Line.sub.1 ", Cancer Research, 46:4933-4937 (1986).
Tormey, et al., "Evaluation of Tamoxifen Doeses With and Without Fluoxymesterone in Advanced Breast Cancer", Annals of Internal Medicine, vol. 98, No. 2, pp. 139-144 (1983).
Dialog, Cancerlit Abstract No. 88744134 (1988).
A. Manni, et al., Cancer Research, Jun. 10, 1987, vol. 37, No. 4, pp. 1216-1219.
Annu. Meet. Am. Assoc. Cancer Research, 29:A930, 1988-Jun. 30, 1988.
F. Pannuti, et al., Panminerva Medica, 1981, Vo. 23, No. 3, pp. 157-160.
Chemical Abstracts, vol. 97, No. 85558p, Nov. 4, 1992.
Chemical Abstracts, vol. 100, No. 203835g, Aug. 23, 1984.
Chemical Abstracts, vol. 104, No. 998x, Jan. 30, 1986.
International Search Report on PCT/CA 90/00076.
CA 103:134186, Santen et al. (1984).
Hadley, Endocrinology [1984 Prentice-Hall Englewood, New Jersey], p. 463.

Affiliated with

Also associated with

Rating

Combination therapy for the treatment of estrogen-sensitive dise does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Combination therapy for the treatment of estrogen-sensitive dise, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Combination therapy for the treatment of estrogen-sensitive dise will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-1056214